Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]

Abstract

Neil C Barnes, 1, 2 Dave Singh, 3 David A Lipson 4, 5 1Respiratory Therapy Area, GlaxoSmithKline, Middlesex, UK; 2William Harvey Institute, Bart’s and the London School of Medicine and Dentistry, London, UK; 3Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 4Clinical Sciences, GlaxoSmithKline, Collegeville, PA, USA; 5Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USACorrespondence: Neil C BarnesGlaxoSmithKline, 980 Great West Road, London, TW8 9GS, UKEmail [email protected]  View the original paper by Lodise and colleaguesA Response to Letter has been published for this article.

Keywords

• n/a